GlassScriptPhysician profile
John Ponugupati
NPI 1124274303
$3,161.17
in general payments reported to CMS, 2019-2025
26 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $255 · 2021: $136 · 2022: $396 · 2023: $299 · 2024: $472 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $569.24 | 2019-2025 | Reblozyl, Breyanzi |
| Glaxosmithkline, LLC. | $411.08 | 2020-2025 | Jemperli |
| Janssen Biotech, INC. | $384.35 | 2019-2023 | Darzalex, Carvykti, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $376.88 | 2019-2024 | Lynparza |
| Genentech USA, INC. | $215.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $187.61 | 2019-2022 | |
| Pfizer INC. | $143.97 | 2019-2024 | |
| Galvanize Therapeutics, INC | $127.00 | 2025 | Aliya System |
| Abbvie INC. | $125.00 | 2025 | |
| Rigel Pharmaceuticals, INC. | $105.27 | 2019-2023 | Rezlidhia, Tavalisse |
| Celgene Corporation | $93.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $72.90 | 2019-2022 | |
| Astellas Pharma US INC | $53.69 | 2019-2022 | |
| Amgen INC. | $46.52 | 2019 | |
| Lilly USA, LLC | $35.44 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $31.29 | 2019-2020 | |
| Daiichi Sankyo INC. | $26.98 | 2022 | |
| Seagen INC. | $24.01 | 2022 | |
| Beigene USA, INC. | $19.52 | 2022 | |
| Sobi, INC | $19.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.94 | 2022 | |
| Tesaro, INC. | $16.61 | 2019 | |
| Dova Pharmaceuticals | $15.42 | 2020 | |
| Incyte Corporation | $15.29 | 2019 | |
| Medtronic, INC. | $14.27 | 2025 | Emprint |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ponugupati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.